Skip to content

Individualized Non-Invasive Neuromodulation for Central Neurodegenerative Diseases Guided by Multimodal Neural Signal Decoding

Individualized Non-Invasive Neuromodulation for Central Neurodegenerative Diseases Guided by Multimodal Neural Signal Decoding

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2600128574
Enrollment
Unknown
Registered
2026-07-22
Start date
2026-07-22
Completion date
Unknown
Last updated
2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Parkinson's disease and/or cognitive impairment

Interventions

Transcranial light stimulation group:Transcranial light stimulation group

Sponsors

The Second Affiliated Hospital of Soochow University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
50 Years to No maximum

Inclusion criteria

Inclusion criteria: 1.Aged 50 years or older; 2.Parkinson’s disease group: Patients with clinically definite Parkinson’s disease according to the latest revised diagnostic criteria issued by the International Parkinson and Movement Disorder Society (MDS), with Hoehn and Yahr stage 1–3;Cognitive impairment group: Patients diagnosed with mild cognitive impairment (MCI) or Alzheimer’s disease (AD) based on internationally and nationally recognized diagnostic criteria; 3.Clinically stable condition, with a stable medication regimen in the past 4 weeks and no definite plan for major adjustment during the study period; 4.Meet the relevant safety criteria for examinations and procedures if receiving non-invasive neuromodulation intervention; 5.Able to understand the purpose and procedures of the study, voluntarily participate in this clinical trial, and have signed a written informed consent form.

Exclusion criteria

Exclusion criteria: 1.Presence of other severe neurological diseases (e.g., stroke sequelae, brain tumor, inflammatory demyelinating disease) or severe mental disorders that may interfere with clinical assessment; 2.History of epilepsy or at high risk of convulsions; 3.Contraindications to MRI/EEG examinations (e.g., implanted devices incompatible with MRI, severe claustrophobia precluding scanning); 4.Severe unstable medical conditions (e.g., decompensated heart/respiratory failure, severe hepatic or renal insufficiency); 5.Participation in other clinical trials that may interfere with the evaluation of primary endpoints, or receipt of systematic neuromodulation therapy within the past 1 month (defined specifically in each sub-study).

Design outcomes

Primary

MeasureTime frame
Parkinson's disease rating scale score;Mini-Mental State Examination (MMSE) score;Montreal Cognitive Assessment (MoCA) score;

Countries

China

Contacts

Public ContactChunfeng Liu

The Second Affiliated Hospital of Soochow University

liuchunfeng@suda.edu.cn+86 512 6778 3307

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Aug 10, 2026